Press Release

Sygnature Discovery is delighted to announce its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. Read the full press release, here.

About NuChem Sciences

NuChem Sciences, a leading discovery CRO in the North American market, employs over 300 staff across centres of excellence in Montreal and Quebec City, Canada, where the company will continue to operate and drive further market expansion across North America.  

Founded in 2011, NuChem Sciences delivers expert integrated and standalone discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology to global biotech and pharmaceutical companies. Additionally, the company provides protein chemistry services and offers crucial knowledge-based expertise in structural biology at the early stages of drug discovery.

For media enquiries, contact: info@sygnaturediscovery.com

A History of Innovation

Since our founding in 2004, the integrated drug discovery team at Sygnature Discovery has delivered over 40 preclinical compounds and 22 clinical compounds. Our scientists are named on over 170 customer patent applications.